Weight Rebound After Stopping Medication, Muscle Loss During Weight Loss? Two Truths About GLP-1 Weight Loss

This material is for reference by healthcare professionals only

"I lost 20 jin on GLP-1—will it all come back if I stop?" "Am I losing fat or muscle?"—These are the two most frequently asked questions in weight-management clinics. The answers are not as simple as what circulates online: rebound does occur, but it is manageable; muscle loss does happen, but it can be intervened upon. The key is not to treat a "tool" as a "miracle drug," and not to treat "data" as "destiny."

I. Rebound After Stopping: Real, but Exaggerated

The SURMOUNT-4 study provides the most direct answer: participants first lost about 20.9% of their body weight with tirzepatide, then stopped the drug and were observed; after one year, body weight rose by about 14% (partial rebound), but remained significantly better than the placebo group¹.

The mechanism behind this is precisely the "set-point defense" discussed in the previous article:

  • After stopping the drug, ghrelin levels rise again and appetite signals recover
  • Basal metabolic rate remains in "energy-saving mode"
  • The epigenetic memory of fat cells still persists

Key conclusion: GLP-1 is a "management tool," not a "cure." Just as antihypertensive drugs cannot be stopped and glucose-lowering drugs cannot be interrupted, if weight loss is treated as long-term chronic disease management, rebound is not a "failure" but a signal that "treatment needs to continue"².

II. Muscle Loss: Three Truths Behind the Data

"Weight loss causes muscle loss" does happen, but it is often taken out of context. Three key data points:

Truth one: Any weight-loss method causes muscle loss.  Whether through dieting, exercise, or surgery, muscle accounts for about 20-30% of the weight lost during weight reduction. This is not a "side effect" of GLP-1, but an inherent rule of negative energy balance³.

Truth two: The proportion of muscle loss with GLP-1 is not abnormal.  A subgroup analysis of SURMOUNT-1 showed that among the weight lost with tirzepatide, lean body mass (including muscle) accounted for about 25%, comparable to data from lifestyle intervention and bariatric surgery⁴.

Truth three: Muscle loss can be intervened upon.  - Resistance training: Strength training 2-3 times per week can significantly preserve muscle  - Adequate protein: Protein intake of 1.2-1.6 g/kg per day  - New-generation combination regimens: ActRII inhibitors (such as bimagrumab) combined with GLP-1 achieved 22.1% weight loss while muscle loss was only 2.9%, far lower than the 20%+ seen with traditional regimens⁵

III. Practical Recommendations for Clinicians

Regarding rebound:  1. Set reasonable expectations—GLP-1 is long-term management, not "a few injections and done"  2. Establish a "maintenance plan" before stopping (lifestyle + maintenance dose if necessary)  3. At follow-up visits, focus on the "slope of the weight curve" rather than a single weight value

Regarding muscle:  1. Prescribe an "exercise prescription" alongside the medication (resistance training first)  2. Focus on functional indicators (grip strength, gait speed, stair climbing), not just the body fat scale  3. For high-risk groups (older adults, sarcopenia, rapid weight losers), prioritize combination regimens

IV. One-Sentence Summary

In the GLP-1 era, the core proposition of weight-loss medicine has changed:

It is no longer "Can you lose weight?" but "Can you lose weight healthily and sustainably?"

Muscle loss and rebound after stopping medication are not "crashes," but reminders that weight loss is a marathon requiring scientific management and long-termism, not a 100-meter sprint.

References:

  1. Aronne LJ, et al. JAMA. 2024;331(1):38-48. PMID: 38078870.
  2. Wharton S, et al. Obes Rev. 2020;21(9):e13034. PMID: 32390301.
  3. Heymsfield SB, et al. Am J Clin Nutr. 2014;100(3):765-772. PMID: 25057156.
  4. Jastreboff AM, et al. N Engl J Med. 2022;387(3):205-216. PMID: 35658024.
  5. Heymsfield SB, et al. JAMA. 2024;331(8):680-692. PMID: 38324367.

This material is intended for reference by healthcare professionals only and is not promotional material for the general public. © 2026 Sun Holy Hua (Beijing) Medical Technology Co., Ltd.